Compare Gilead Sciences, Inc. (GILD) vs Block Inc (XYZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Block Inc — how do they compare? Gilead Sciences, Inc. trades at $151.17 (market cap $182.40B), while Block Inc trades at $77.24 (market cap $45.20B). The key difference: Gilead Sciences, Inc. is far larger — about 4× Block Inc's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Block Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Block Inc for 78 Days on average.
| GILD | XYZ | |
|---|---|---|
Market Cap | $182.40B | $45.20B |
Volume | 4,469,821 | 8,386,094 |
Sector | Health | Technology |
52-Week High | $155.80 | $84.85 |
52-Week Low | $117.18 | $49.04 |
Typical Hold Time | 111 Days | 78 Days |
Enterprise Value | $205.46B | $40.10B |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, showing modest daily gains of 0.17% with strong technical support at $145. The company demonstrates robust fundamentals with Q2 2026 earnings beating expectations despite a net loss, while maintaining a high gross margin of 79.59%. Recent developments include expanded HIV prevention drug access across Latin America through a PAHO partnership, positioning the company for growth in key therapeutic areas.
GILD presents a mixed outlook with strong analyst support (65.5% buy ratings) and a $151.57 price target offering 3% upside, but faces headwinds from negative net income margins and elevated debt levels. The stock's valuation appears reasonable with a P/E of 17.84, though investors should monitor the company's ability to translate top-line strength into sustainable profitability amid competitive pressures.
XYZ trades at $75.21, down 1.13% on the day, with technical indicators showing bearish momentum near key support at $74. The company reported mixed Q3 2026 earnings with two beats and one miss, while revenue growth has slowed to 0.4% year-over-year in 2025. Analyst consensus remains strongly bullish with a $97.47 price target, representing 30% upside potential from current levels.
XYZ faces valuation concerns with a high P/E ratio of 134.34, though strong institutional support and expanding merchant partnerships provide growth catalysts. Key risks include declining net income margins and negative cash flow trends, requiring careful monitoring of upcoming Q3 2026 results for directional clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Block Inc
Founded in 2009, Block provides payment acquiring services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. Block has operations in Canada, Japan, Australia, and the United Kingdom
Read more on XYZ →
